Want to see HK:9926 full AI Analyst Report?
Akeso, Inc. (9926) AI Stock Analysis
Top Page
Akeso, Inc.
(HKEX:9926)
The score is weighed down primarily by deteriorating profitability and negative operating/free cash flow despite strong revenue growth and high gross margins. Technicals add caution with the stock trading below key moving averages, while valuation is constrained by losses (negative P/E) and no dividend support.
Akeso, Inc. (9926) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 75.07B
- Dividend Yield
- ―
- Average Volume (3M)
- 11.45M
- Price to Earnings (P/E)
- -66.5
- Beta (1Y)
- 0.42
- Revenue Growth
- 42.47%
- EPS Growth
- -15.80%
- Country
- Hong Kong
- Employees
- 4,082
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Akeso, Inc. Business Overview & Revenue Model
Company Description
Akeso, Inc. is a biopharmaceutical enterprise dedicated to the discovery, development, manufacturing, and commercialization of therapeutic solutions. The company boasts a diverse pipeline, with a significant focus on oncology. Its cancer-focused trea...
How the Company Makes Money
Akeso makes money primarily through (1) product sales of any therapies it commercializes itself (where revenue is recognized from selling approved drugs into the market through its commercial channels), and (2) collaboration and licensing arrangement...
Akeso, Inc. Financial Statement Overview
Summary
Strong 2025 revenue rebound and very high gross margins are positives, but profitability has deteriorated into sizable losses (2024–2025) and cash flow has weakened materially. Balance sheet leverage looks moderate, yet rising debt alongside negative operating and free cash flow increases funding risk.
Income Statement
54NeutralBalance Sheet
63PositiveCash Flow
42Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.40B | 2.98B | 2.12B | 4.53B | 837.66M | 225.63M |
| Gross Profit | 2.58B | 2.34B | 1.83B | 4.39B | 734.54M | 195.41M |
| EBITDA | -779.43M | -656.33M | -536.34M | 2.17B | -1.27B | -1.31B |
| Net Income | -952.25M | -1.08B | -514.51M | 2.03B | -1.17B | -1.07B |
Balance Sheet | ||||||
| Total Assets | 16.22B | 16.01B | 12.75B | 9.18B | 5.50B | 4.81B |
| Cash, Cash Equivalents and Short-Term Investments | 9.16B | 9.18B | 7.32B | 4.88B | 2.29B | 2.65B |
| Total Debt | 4.98B | 4.56B | 3.95B | 2.99B | 1.88B | 859.42M |
| Total Liabilities | 7.86B | 7.06B | 6.00B | 4.66B | 2.95B | 1.53B |
| Stockholders Equity | 8.48B | 9.05B | 6.81B | 4.69B | 2.64B | 3.16B |
Cash Flow | ||||||
| Free Cash Flow | -1.24B | -1.83B | -1.11B | 1.59B | -2.02B | -1.71B |
| Operating Cash Flow | -629.47M | -1.11B | -527.62M | 2.47B | -1.24B | -1.00B |
| Investing Cash Flow | -3.30B | -4.17B | -1.52B | -4.00B | -889.75M | -579.59M |
| Financing Cash Flow | 3.53B | 3.72B | 3.39B | 960.89M | 1.49B | 1.59B |
Akeso, Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:9926, the sentiment is Negative. The current price of 81.50 is below the 20-day moving average (MA) of 95.29, below the 50-day MA of 94.69, and below the 200-day MA of 106.64, indicating a bearish trend. The MACD of -4.37 indicates Positive momentum. The RSI at 37.11 is Neutral, neither overbought nor oversold. The STOCH value of 22.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:9926.
Akeso, Inc. Peers Comparison
Overall Rating
HK:180181Outperform
HK:999566Neutral
HK:269664.6Neutral- HK:992648Neutral
HK:968846Neutral
HK:187741.25Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:1801 | 81Outperform | HKD 139.32B | 95.59 | 6.06% | ― | 42.64% | 9.67% |
| HK:9995 | 66Neutral | HKD 51.82B | 7.89 | 105.60% | ― | 292.84% | ― |
| HK:2696 | 65Neutral | HKD 26.75B | 26.18 | 20.41% | ― | 32.63% | 8.74% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:9926 | 48Neutral | HKD 76.70B | -66.50 | -10.86% | ― | 42.47% | -15.80% |
| HK:9688 | 46Neutral | HKD 21.69B | -12.70 | -27.40% | ― | 5.38% | 16.86% |
| HK:1877 | 41Neutral | HKD 30.07B | -69.15 | -7.23% | ― | 35.82% | 54.40% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:9926 | Akeso, Inc. | 81.50 | -36.80 | -31.11% | |
| HK:1801 | Innovent Biologics | 79.75 | -10.45 | -11.59% | |
| HK:9688 | Zai Lab Ltd | 17.37 | -3.65 | -17.36% | |
| HK:9995 | RemeGen Co. Ltd. Class H | 64.85 | -28.00 | -30.16% | |
| HK:1877 | Shanghai Junshi Biosciences Co., Ltd. Class H | 15.26 | -11.44 | -42.85% | |
| HK:2696 | Shanghai Henlius Biotech, Inc. Class H | 49.06 | -20.04 | -29.00% |
Akeso, Inc. Corporate Events
Akeso’s Ivonescimab Delivers Phase III Survival Gains in Biliary Tract Cancer
Akeso has reported late-breaking Phase III data from its HARMONi-GI1 trial, showing ivonescimab plus chemotherapy significantly improved survival outcomes versus durvalumab plus chemotherapy in first-line treatment of advanced biliary tract cancer. T...
Akeso Raises HK$1.94 Billion Through Institutional Share Placing
Akeso, Inc. has completed a placing of 20,000,000 new shares under its general mandate, executed by a sole coordinator and bookrunner. The shares were placed at HK$97.76 each to at least six independent professional and institutional investors, expan...
Akeso to Raise HK$1.94 Billion via Discounted Share Placing
Akeso, Inc. has entered into a placing agreement to issue 20,000,000 new shares at HK$97.76 each to at least six institutional or professional investors, representing about 2.17% of its existing share capital. The placing price reflects a discount of...
Akeso’s Ivonescimab Tops Pembrolizumab in Key Lung Cancer Survival Trial
Akeso, Inc. reported that its PD-1/VEGF bispecific antibody ivonescimab delivered a statistically significant and clinically meaningful overall survival benefit over Merck’s pembrolizumab in the Phase III HARMONi-2 trial. The study, involving 3...
Akeso Narrows Interim Loss as Revenue Jumps Nearly 28%
Akeso, Inc. reported that its revenue for the six months ended June 30, 2026 rose 27.92% year-on-year to RMB1,805.7 million, driven mainly by a 28.65% increase in commercial sales to RMB1,803.2 million and a modest contribution from license income. G...
Akeso’s Ivonescimab Delivers Phase III Survival Gain in Biliary Tract Cancer
Akeso, Inc., a Hong Kong-listed biopharmaceutical developer, has built its oncology franchise around ivonescimab, a first-in-class PD-1/VEGF bispecific antibody. The drug already has multiple approved and reimbursed indications in non-small cell lung...
Akeso Schedules Board Meeting to Approve 2026 Interim Results
Akeso, Inc. has scheduled a board meeting for August 27, 2026, to review and approve the interim results for the six months ended June 30, 2026, and to authorize their publication. The announcement signals the upcoming disclosure of the company’...
Akeso Wins Third NMPA Nod for Ivonescimab in Advanced Lung Cancer
Akeso has secured National Medical Products Administration approval in China for a third major indication of its bi-specific antibody ivonescimab, branded 依達方, as a first-line treatment in combination with chemotherapy for advanc...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 15, 2026